ArticleScientific reports2026
Establishment and characterization of NKMS-1, a novel mouse NK cell line.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Following the recent success of genetically modified T cells in cancer immunotherapy, an increasing number of studies are focusing on natural killer (NK) cells as an alternative to T cells. The characteristics of NK cells may help overcome the disadvantages of T cell-based therapy, such as graft-versus-host disease, cytokine release syndrome, and the high cost and long preparation time of the treatment. To accelerate the development of NK cell-based therapies, the establishment of appropriate mouse models using murine NK cells would be beneficial. Although several groups have reported the establishment of murine NK cell clones, only a few are currently available. In this study, we established a murine NK cell line, NKMS-1, which can grow in a standard cell culture medium supplemented with interleukin-2 and can be stored frozen, retaining cytotoxicity and the ability to be genetically modified. These properties make the cell line suitable for studying NK cell-based cancer immunotherapy and NK cell biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.